Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Cash from Financing Activities (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Cash from Financing Activities for 3 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 995.89% to $8.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $202.5 million, a 61088.82% increase, with the full-year FY2025 number at $202.5 million, up 61088.82% from a year prior.
  • Cash from Financing Activities was $8.1 million for Q4 2025 at Nuvation Bio, up from $501000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $193.4 million in Q2 2025 to a low of -$1.5 million in Q3 2024.
  • A 3-year average of $17.0 million and a median of $215500.0 in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 2097.4% in 2024, then soared 6938.68% in 2025.
  • Nuvation Bio's Cash from Financing Activities stood at $120000.0 in 2023, then tumbled by 850.0% to -$900000.0 in 2024, then soared by 995.89% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Cash from Financing Activities are $8.1 million (Q4 2025), $501000.0 (Q3 2025), and $193.4 million (Q2 2025).